GRITSTONE ONCOLOGY, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 29, 2018Investors’ Rights Agreement • August 23rd, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 29, 2018, by and among Gritstone Oncology, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement (as defined below)) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
LEASE BETWEEN EMERY STATION JOINT VENTURE LLC (Landlord) and GRITSTONE ONCOLOGY, INC. (Tenant) EMERY STATION I Emeryville, CaliforniaLease • August 23rd, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • California
LICENSE AGREEMENT by and between GRITSTONE ONCOLOGY, INC. on the one hand, and ARBUTUS BIOPHARMA CORPORATION and PROTIVA BIOTHERAPEUTICS INC., on the other hand Dated as of October 16, 2017License Agreement • August 23rd, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into as of October 16, 2017 (the “Effective Date”), by and between (a) Gritstone Oncology, Inc., a Delaware corporation having a place of business at 5858 Horton Street, Suite 210, Emeryville, California 94608, U.S.A. (“Gritstone”), on the one hand, and (b) Protiva Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Arbutus Biopharma Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“ABUS” and together with Protiva, “Arbutus”), on the other hand. Capitalized terms when used in this Agreement have the meanings set forth in Article I.
